BNTX Latest Press Releases

-- November 3, 2026 --

BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update Globe Newswire 6:45 AM

-- October 26, 2026 --

A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets Globe Newswire 8:53 AM

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer Globe Newswire 5:00 AM

-- October 25, 2026 --

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy Globe Newswire 3:30 AM

-- October 22, 2026 --

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer Globe Newswire 6:45 AM

-- October 20, 2026 --

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026 Globe Newswire 6:45 AM

-- October 19, 2026 --

BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 Globe Newswire 6:45 AM

-- October 14, 2026 --

BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX) PRNewswire 3:22 PM

-- October 13, 2026 --

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer Globe Newswire 6:45 AM

-- September 15, 2026 --

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat Globe Newswire 9:00 AM

-- September 14, 2026 --

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients Globe Newswire 4:00 AM

-- August 27, 2026 --

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine Business Wire 4:30 PM

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine Globe Newswire 4:30 PM

-- August 26, 2026 --

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer's Biggest Opportunity Globe Newswire 9:20 AM

-- August 20, 2026 --

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 Globe Newswire 5:30 AM

-- August 4, 2026 --

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update Globe Newswire 6:45 AM

-- August 3, 2026 --

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer Globe Newswire 5:00 AM

-- July 29, 2026 --

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union Business Wire 4:30 PM

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union Globe Newswire 4:30 PM

-- July 21, 2026 --

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026 Globe Newswire 6:45 AM

-- June 25, 2026 --

The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution Globe Newswire 11:39 AM

Market Data Delayed 15 Minutes